Healthy ageing: Herpes zoster infection and the role of zoster vaccination

• Published in: npj vaccines Vol. 8; no. 1; p. 184
• Main Authors: Curran, Desmond, Doherty, T. Mark, Lecrenier, Nicolas, Breuer, Thomas
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group 28.11.2023; Nature Publishing Group UK; Nature Portfolio
• Subjects: Aging; Disease; Health promotion; Health risks; Hearing loss; Herpes viruses; Infectious diseases; Myocardial infarction; Older people; Quality of life; Review; Vaccines
• ISSN: 2059-0105; 2059-0105
• DOI: 10.1038/s41541-023-00757-0

Populations are ageing worldwide, with considerable time lived in ill-health, putting upwards pressure on healthcare budgets. Healthy ageing is defined as maintaining functional ability, including the ability to: meet basic needs; learn, grow and make decisions; be mobile; build and maintain relationships; and contribute to society. The risk and impact of infectious diseases increase with age due to immunosenescence. Vaccination can help to prevent disease in older adults, promoting healthy ageing and active lives. Herpes zoster (HZ) occurs when the varicella zoster virus is reactivated due to declining immunity. HZ is common, with a lifetime risk of one-third, and increases in incidence with age. HZ is associated with severe and intense pain, substantially affecting the functional status of patients as well as their overall health-related quality of life. HZ and its complications may result in prolonged morbidity, including persistent pain (post-herpetic neuralgia, PHN), hearing impairment, vision loss and increased risk of stroke and myocardial infarction. HZ and PHN are difficult to treat, substantiating the benefits of prevention. Vaccines to prevent HZ include a recombinant zoster vaccine (RZV). RZV has shown efficacy against the HZ burden of disease and HZ burden of interference on activities of daily living of over 90% in immunocompetent adults aged ≥50 years. Vaccine efficacy against HZ was maintained at over 70% at 10 years post-vaccination. Adult vaccination, including against HZ, has the potential to reduce burden of disease, thus helping to maintain functioning and quality of life to support healthy ageing in older adults.